Valuation: TapImmune Inc

Market Cap 21.84M 19.09M 17.61M 16.24M 30.6M 2.1B 31.28M 211M 82.8M 1.03B 82.03M 80.23M 3.55B P/E 2026 *
-1.36x
P/E 2027 * -1.29x
Enterprise Value 21.84M 19.09M 17.61M 16.24M 30.6M 2.1B 31.28M 211M 82.8M 1.03B 82.03M 80.23M 3.55B EV / Sales 2026 *
7.72x
EV / Sales 2027 * 1.09x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-12.24% - - 21.84M
-1.29%-3.11%-0.35%+2.64% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.47% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+1.12%+1.91%+14.54%+15.44% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +0.47%+0.03%+65.98%+97.47% 27.07B
Weighted average by Cap. -0.05%-0.18%+79.44%+122.31%

Financials

2026 *2027 *
Net sales 2.83M 2.47M 2.28M 2.1M 3.97M 273M 4.05M 27.28M 10.73M 133M 10.63M 10.4M 460M 20.09M 17.55M 16.2M 14.93M 28.14M 1.93B 28.76M 194M 76.15M 947M 75.43M 73.78M 3.26B
Net income -19.36M -16.92M -15.61M -14.39M -27.13M -1.86B -27.73M -187M -73.4M -913M -72.71M -71.12M -3.14B -19.89M -17.38M -16.04M -14.79M -27.87M -1.92B -28.49M -192M -75.41M -938M -74.7M -73.06M -3.23B
Net Debt - -
Logo TapImmune Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-